Cargando…
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?
Our understanding of the immunopathological features of type 1 diabetes (T1D) has greatly improved over the past two decades and has shed light on disease heterogeneity dictated by multiple immune, metabolic, and clinical parameters. This may explain the limited effects of immunotherapies tested so...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031881/ https://www.ncbi.nlm.nih.gov/pubmed/35455658 http://dx.doi.org/10.3390/jpm12040542 |